We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEX Corporation (IEX - Free Report) reported impressive first-quarter 2023 results. The company’s earnings surpassed the Zacks Consensus Estimate by 3%, whereas sales beat the same by 3.4%.
In the reported quarter, IDEX’s adjusted earnings were $2.09 per share, beating the Zacks Consensus Estimate of $2.03 per share. Our estimate for first-quarter adjusted earnings was $2.01 per share. On a year-over-year basis, the bottom line increased 6.6% from the year-ago quarter’s $1.96. Healthy segmental results favorably impacted the quarter’s earnings.
Earnings for the first quarter exceeded management’s projection of $1.98-$2.03 per share.
Revenue Details
In the quarter under review, IDEX’s net sales were $845.4 million, reflecting year-over-year growth of 12.6%. Organic sales in the quarter increased 6% year over year, higher than 3-5% growth expected by IEX. Acquired assets boosted sales 9%. Foreign currency translation left a negative impact of 2%.
IDEX’s top line surpassed the Zacks Consensus Estimate of $817 million. Our estimate for net sales in the reported quarter was $823.2 million.
IEX reports net sales under three business segments, the results of which are discussed below:
Revenues from Fluid & Metering Technologies totaled $321.8 million, increasing 18% year over year. Our estimate for segmental revenues was $301.9 million. Organic sales were up 9% and synergies from acquired assets added 11%. Foreign currency translation left a negative impact of 2%.
Revenues from Health & Science Technologies totaled $351 million, reflecting year-over-year growth of 11%. Our estimate for segmental revenues was $346.4 million. Organic sales in the quarter increased 3% year over year, while acquired assets boosted sales 11%. Foreign currency translation left a negative impact of 3%.
Revenues from Fire & Safety/Diversified Products totaled $174.4 million, rising 6% year over year. Our estimate for segmental revenues was $175.8 million. The results were aided by a 9% increase in organic sales but suffered 3% forex woes.
IDEX Corporation Price, Consensus and EPS Surprise
In the quarter under review, IDEX’s cost of sales increased 13.3% year over year to $462.9 million. The gross profit was $382.5 million, up 11.7% year over year, while the gross margin was 45.2%, compared with 45.6% reported in the year-ago quarter.
Selling, general and administrative expenses increased 22.9% year over year to $189.7 million. The same represented 22.4% of revenues. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in the quarter under review increased 7% year over year to $229.8 million. The adjusted EBITDA margin decreased 140 bps year over year to 28.6%.
The operating income was $192.3 million, up 2.5% year over year, whereas the margin was 22.7%, down 230 bps year over year. Interest expenses in the quarter increased 37.9% year over year to $13.1 million.
Balance Sheet and Cash Flow
While exiting the first quarter, IDEX’s cash and cash equivalents decreased 18.7% to $510.7 million, compared with $430.2 million recorded at the end of fourth-quarter 2022. Long-term borrowings were $1,470.7 million, compared with $1,468.7 million recorded at the end of fourth-quarter 2022.
In the first three months of 2023, IDEX generated net cash of $147.9 million from operating activities, increasing 85.7% from the year-ago period. Capital used for purchasing property, plant and equipment was $26.6 million, compared with $16.1 million in December 2022. Free cash flow was $121.3 million, up 90.7% year over year.
IEX paid out dividends totaling $45.5 million. However, the company did not repurchase any common stock in the quarter.
IEX did not spend any amount on acquisitions in the first three months of 2023.
Outlook
For second-quarter 2023, IDEX anticipates adjusted earnings of $2.10-$2.13 per share and approximately 3% growth in organic sales from the respective year-ago readings.
IEX predicts EPS of $1.86-$1.89 per share for second-quarter 2023.
For 2023, IDEX anticipates adjusted earnings of $8.25-$8.55 per share, compared with $8.50-$8.80 per share anticipated earlier. Full-year earnings are predicted to be $7.30-$7.60 per share, compared with $7.55-$7.85 per share expected earlier.
Organic sales are predicted to grow 0-3% for 2023, compared with 1-5% predicted earlier.
Zacks Rank & Stocks to Consider
IEX currently carries a Zacks Rank #3 (Hold). Some top-ranked companies from the Industrial Products sector are discussed below:
ALG’s earnings surprise in the last four quarters was 6.0%, on average. In the past 60 days, estimates for Alamo’s 2023 earnings have increased 7.5%. The stock has gained 17.5% in the past six months.
Ingersoll Rand Inc. (IR - Free Report) presently sports a Zacks Rank of 1. IR’s earnings surprise in the last four quarters was 8.5%, on average.
In the past 60 days, estimates for Ingersoll Rand’s 2023 earnings have increased 3.3%. The stock has rallied 5.8% in the past six months.
Allegion plc (ALLE - Free Report) presently carries a Zacks Rank #2 (Buy). ALLE’s earnings surprise in the last four quarters was 10.3%, on average.
In the past 60 days, Allegion’s earnings estimates have increased 1.1% for 2023. The stock has gained 1.2% in the past six months.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
IDEX (IEX) Q1 Earnings & Revenues Beat, Increase Y/Y
IDEX Corporation (IEX - Free Report) reported impressive first-quarter 2023 results. The company’s earnings surpassed the Zacks Consensus Estimate by 3%, whereas sales beat the same by 3.4%.
In the reported quarter, IDEX’s adjusted earnings were $2.09 per share, beating the Zacks Consensus Estimate of $2.03 per share. Our estimate for first-quarter adjusted earnings was $2.01 per share. On a year-over-year basis, the bottom line increased 6.6% from the year-ago quarter’s $1.96. Healthy segmental results favorably impacted the quarter’s earnings.
Earnings for the first quarter exceeded management’s projection of $1.98-$2.03 per share.
Revenue Details
In the quarter under review, IDEX’s net sales were $845.4 million, reflecting year-over-year growth of 12.6%. Organic sales in the quarter increased 6% year over year, higher than 3-5% growth expected by IEX. Acquired assets boosted sales 9%. Foreign currency translation left a negative impact of 2%.
IDEX’s top line surpassed the Zacks Consensus Estimate of $817 million. Our estimate for net sales in the reported quarter was $823.2 million.
IEX reports net sales under three business segments, the results of which are discussed below:
Revenues from Fluid & Metering Technologies totaled $321.8 million, increasing 18% year over year. Our estimate for segmental revenues was $301.9 million. Organic sales were up 9% and synergies from acquired assets added 11%. Foreign currency translation left a negative impact of 2%.
Revenues from Health & Science Technologies totaled $351 million, reflecting year-over-year growth of 11%. Our estimate for segmental revenues was $346.4 million. Organic sales in the quarter increased 3% year over year, while acquired assets boosted sales 11%. Foreign currency translation left a negative impact of 3%.
Revenues from Fire & Safety/Diversified Products totaled $174.4 million, rising 6% year over year. Our estimate for segmental revenues was $175.8 million. The results were aided by a 9% increase in organic sales but suffered 3% forex woes.
IDEX Corporation Price, Consensus and EPS Surprise
IDEX Corporation price-consensus-eps-surprise-chart | IDEX Corporation Quote
Margin Profile
In the quarter under review, IDEX’s cost of sales increased 13.3% year over year to $462.9 million. The gross profit was $382.5 million, up 11.7% year over year, while the gross margin was 45.2%, compared with 45.6% reported in the year-ago quarter.
Selling, general and administrative expenses increased 22.9% year over year to $189.7 million. The same represented 22.4% of revenues. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) in the quarter under review increased 7% year over year to $229.8 million. The adjusted EBITDA margin decreased 140 bps year over year to 28.6%.
The operating income was $192.3 million, up 2.5% year over year, whereas the margin was 22.7%, down 230 bps year over year. Interest expenses in the quarter increased 37.9% year over year to $13.1 million.
Balance Sheet and Cash Flow
While exiting the first quarter, IDEX’s cash and cash equivalents decreased 18.7% to $510.7 million, compared with $430.2 million recorded at the end of fourth-quarter 2022. Long-term borrowings were $1,470.7 million, compared with $1,468.7 million recorded at the end of fourth-quarter 2022.
In the first three months of 2023, IDEX generated net cash of $147.9 million from operating activities, increasing 85.7% from the year-ago period. Capital used for purchasing property, plant and equipment was $26.6 million, compared with $16.1 million in December 2022. Free cash flow was $121.3 million, up 90.7% year over year.
IEX paid out dividends totaling $45.5 million. However, the company did not repurchase any common stock in the quarter.
IEX did not spend any amount on acquisitions in the first three months of 2023.
Outlook
For second-quarter 2023, IDEX anticipates adjusted earnings of $2.10-$2.13 per share and approximately 3% growth in organic sales from the respective year-ago readings.
IEX predicts EPS of $1.86-$1.89 per share for second-quarter 2023.
For 2023, IDEX anticipates adjusted earnings of $8.25-$8.55 per share, compared with $8.50-$8.80 per share anticipated earlier. Full-year earnings are predicted to be $7.30-$7.60 per share, compared with $7.55-$7.85 per share expected earlier.
Organic sales are predicted to grow 0-3% for 2023, compared with 1-5% predicted earlier.
Zacks Rank & Stocks to Consider
IEX currently carries a Zacks Rank #3 (Hold). Some top-ranked companies from the Industrial Products sector are discussed below:
Alamo Group Inc. (ALG - Free Report) presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks.
ALG’s earnings surprise in the last four quarters was 6.0%, on average. In the past 60 days, estimates for Alamo’s 2023 earnings have increased 7.5%. The stock has gained 17.5% in the past six months.
Ingersoll Rand Inc. (IR - Free Report) presently sports a Zacks Rank of 1. IR’s earnings surprise in the last four quarters was 8.5%, on average.
In the past 60 days, estimates for Ingersoll Rand’s 2023 earnings have increased 3.3%. The stock has rallied 5.8% in the past six months.
Allegion plc (ALLE - Free Report) presently carries a Zacks Rank #2 (Buy). ALLE’s earnings surprise in the last four quarters was 10.3%, on average.
In the past 60 days, Allegion’s earnings estimates have increased 1.1% for 2023. The stock has gained 1.2% in the past six months.